pembrolizumab
merck
['pembro', 'sclc', 'lcsm,(-blcsm)', 'nsclc']
pembrolizumab plus chemo does not significantly improve survival in tki-resistant, egfr+ nsclc #asco23 #asco2023 #lcsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.